Facebook Tracking Image

National Comprehensive Cancer Network

Home      25th anniversary graphic
NCCN Guidelines®
About The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Development and Update of the NCCN Guidelines
Recent Updates to NCCN Guidelines®
NCCN Guidelines Panels-Meeting Schedule
NCCN Categories of Evidence and Consensus
NCCN Categories of Preference
NCCN Guidelines® Steering Committee
Transparency: Process and Recommendations
Submission Request to the NCCN Guidelines Panels
Submission Request History
NCCN Compendium®
About the NCCN Compendium®
Subscribe to the NCCN Compendium
No Longer Recommended Uses
NCCN Compendium User Guide
NCCN Framework for Resource Stratification of NCCN Guidelines
(NCCN Framework™)
//modal popup library

NCCN Guidelines® & Clinical Resources

NCCN Guidelines®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are posted with the latest update date and version number.

The NCCN Guidelines are copyrighted by the NCCN. All rights reserved. NCCN Guidelines and illustrations (including algorithms) may not be reproduced in any form for any purpose without the express written permission of the NCCN. Permissions Requests Section.

Click here to view the NCCN Guidelines Panel Members individual disclosures

NCCN Guidelines for Treatment of Cancer by Site

NCCN Guidelines for Detection, Prevention, & Risk Reduction

NCCN Guidelines for Supportive Care

NCCN Guidelines for Specific Populations

NCCN Guidelines for Patients

The NCCN guidelines are FREE! Register for a free account, then click on the cancer types below to display a drop down of options. If you are still having an issue, please contact us.

If you can see this message there appears to be an issue with the javascript in your browser. Please click here to view the NCCN Guidelines without javascript.

NCCN GUIDELINES FOR TREATMENT OF CANCER BY SITE

Acute Lymphoblastic Leukemia (Pediatric and AYA)   New
Basal Cell Skin Cancer (See Non-Melanoma Skin Cancers)
Bone Cancer   
Breast Cancer   
Cancer of Unknown Primary (See Occult Primary)
Central Nervous System Cancers   
Cutaneous Melanoma (See Melanoma)
Dermatofibrosarcoma Protuberans (See Non-Melanoma Skin Cancers)
Endometrial Cancer (See Uterine Neoplasms)
Fallopian Tube Cancer (See Ovarian Cancer)
Head and Neck Cancers   
Melanoma
Uveal Melanoma   
Merkel Cell Carcinoma (See Non-Melanoma Skin Cancers)
Multiple Myeloma/Other Plasma Cell Neoplasms
Neuroendocrine and Adrenal Tumors   
Non-Hodgkin Lymphomas
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (See Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma)
B-Cell Lymphomas   
Hairy Cell Leukemia (See Hairy Cell Leukemia)
Pediatric Aggressive Mature B-Cell Lymphomas   New
Primary Cutaneous Lymphomas   
T-Cell Lymphomas   
Non-Melanoma Skin Cancers
Ovarian Cancer   
Primary Peritoneal Cancer (See Ovarian Cancer)
Soft Tissue Sarcoma   
Squamous Cell Skin Cancer (See Non-Melanoma Skin Cancers)
Thyroid Carcinoma   

NCCN GUIDELINES FOR DETECTION, PREVENTION, & RISK REDUCTION


Cervical Cancer Screening   

The NCCN Guidelines Panel for Cervical Cancer Screening endorses the following guidelines:

  • For the prevention and early detection of cervical cancer: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-542. Available at: https://doi.org/10.1309/AJCPTGD94EVRSJCG
  • For the management of abnormal cervical screening tests and cancer precursors: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17(5 Suppl 1):S1-S27. Available at: http://www.asccp.org/
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic   
Genetic/Familial High-Risk Assessment: Colorectal   
Prostate Cancer Early Detection   

NCCN GUIDELINES FOR SUPPORTIVE CARE


Antiemesis   
Cancer- and Chemotherapy-Induced Anemia (See Hematopoietic Growth Factors)
Cancer-Associated Venous Thromboembolic Disease   
Cancer-Related Fatigue   
Hematopoietic Cell Transplantation   New
  • NCCN Guidelines
  • Pre-Transplant Recipient Evaluation
  • Management of Graft-Versus-Host Disease
Hematopoietic Growth Factors   
  • NCCN Guidelines
  • Management of Cancer- and Chemotherapy-Induced Anemia
  • Management of Neutropenia
Management of Immunotherapy-Related Toxicities   
  • NCCN Guidelines
  • Immune Checkpoint-Inhibitor Toxicities
  • CAR T-Cell-Related Toxicities
Myeloid Growth Factors (See Hematopoietic Growth Factors)
Prevention and Treatment of Cancer-Related Infections   
Smoking Cessation   
Survivorship   
  • NCCN Guidelines
  • Preventive Health
    • Healthy Lifestyles
      • Physical Activity
      • Nutrition and Weight Management
      • Supplement Use
    • Immunizations and Infections
  • Late Effects/Long-Term Psychosocial and Physical Problems
    • Anthracycline-Induced Cardiac Toxicity
    • Anxiety and Depression
    • Cognitive Function
    • Fatigue
    • Lymphedema
    • Menopause-Related Symptoms
    • Pain
    • Sexual Function (female/male)
    • Sleep Disorders

NCCN GUIDELINES FOR SPECIFIC POPULATIONS


Cancer in People Living with HIV   
Older Adult Oncology   

 

Disclaimer
The NCCN Guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to cancer treatment. The recommendations regarding the uses and indications in the NCCN Compendium have been derived directly from the NCCN Guidelines. The NCCN Compendium represents neither an all-inclusive listing of every drug and biologic nor every appropriate use and indication for drugs and biologics. The NCCN Templates are peer reviewed statements of consensus of their authors derived from the NCCN Guidelines for the conditions the NCCN Templates address. The NCCN Templates are not exhaustive and do not represent the full spectrum of care or treatment options described in the NCCN Guidelines or the NCCN Compendium or include all appropriate approaches or combinations of drugs or biologics for the treatment of cancer. A NCCN Template does not constitute an order.

Web Citation for NCCN Guidelines

Help with Viewing the NCCN Guidelines

Get Adobe Reader

Please note that the guidelines listed are Acrobat PDF files. To view these files the Acrobat Reader plug-in must be installed in your browser. Click here for further instructions and a link to the free download site if needed.

Please maximize your browser window to view these guidelines. Please note that there may be a delay of several seconds to a minute or more, depending on the speed of your connection, as the PDFs download into your browser window.

 

 

 

 

//modal popup markup //end of modal popup markup
Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Accessibility| Contact Us

3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved